Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Lose weight on Zepbound, keep it off with Eli Lilly’s new pill? Data say that works.

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...
BioPharma Dive

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Stocktwits on MSN

Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics

The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable ...
PharmExec

Eli Lilly Announces Topline Results From Phase III Trial Studying Oral GLP-1 Therapy Orforglipron

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...